GlassScriptPhysician profile
Jie Liu
NPI 1396972402
$7,582.62
in general payments reported to CMS, 2019-2025
46 companies · $1,248 in 2025
The $1,248 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,663 · 2020: $750 · 2021: $968 · 2022: $854 · 2023: $903 · 2024: $1,197 · 2025: $1,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,348.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $850.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $752.55 | 2019-2025 | |
| Amgen INC. | $746.68 | 2019-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $662.46 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $627.93 | 2019-2025 | Veozah |
| Pfizer INC. | $494.20 | 2019-2025 | |
| Lilly USA, LLC | $331.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceuticals, INC. | $249.61 | 2021 | |
| Amarin Pharma, INC. | $243.28 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $218.25 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.44 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $189.39 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $181.19 | 2022-2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.54 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $134.49 | 2023-2025 | Cologuard Collection Kit |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $134.24 | 2021-2025 | |
| Emd Serono, INC. | $125.00 | 2024 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $114.32 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $113.49 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.37 | 2020-2022 | |
| Abbott Laboratories | $91.32 | 2020-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $89.48 | 2023-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $84.54 | 2019-2024 | Gardasil 9, Vaqta, Capvaxive |
| Esperion Therapeutics, INC. | $70.01 | 2021-2025 | Nexletol |
| Sumitomo Pharma America, INC. | $66.86 | 2024-2025 | Gemtesa |
| Shield Therapeutics INC | $65.30 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $51.14 | 2020-2021 | |
| Antares Pharma, INC. | $44.00 | 2022 | |
| Eisai INC. | $43.50 | 2020-2021 | |
| Pulmonx Corporation | $40.98 | 2024-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Phathom Pharmaceuticals, INC. | $33.74 | 2024-2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $33.62 | 2019 | |
| Dynavax Technologies Corporation | $26.52 | 2025 | Heplisav-B |
| Abiomed | $26.49 | 2025 | |
| Aytu Biopharma, INC. | $22.83 | 2020 | |
| Calliditas Therapeutics US INC. | $22.11 | 2025 | Tarpeyo |
| Halozyme INC | $20.37 | 2023 | |
| Hikma Pharmaceuticals USA | $20.19 | 2019 | |
| Biogen, INC. | $19.93 | 2025 | Leqembi |
| Phadia US INC. | $18.38 | 2022 | |
| Becton, Dickinson and Company | $15.74 | 2022 | |
| Amneal Pharmaceuticals LLC | $15.57 | 2019 | |
| Gilead Sciences, INC. | $15.05 | 2025 | |
| Radius Health, INC. | $12.77 | 2020 | |
| Shire North American Group INC | $12.21 | 2019 | |
| Getinge USA Sales, LLC | $11.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jie Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.